

# Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Insights, Forecast to 2029

<https://marketpublishers.com/r/G7F7EB2CFB71EN.html>

Date: December 2023

Pages: 112

Price: US\$ 4,900.00 (Single User License)

ID: G7F7EB2CFB71EN

## Abstracts

This report presents an overview of global market for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment revenue, projected growth trends,

production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Teva, AbbVie, Glenmark Pharmaceuticals, Par Pharmaceuticals, Mylan, Sanofi, Novartis, Akorn and Albireo Pharma, etc.

### By Company

Teva

AbbVie

Glenmark Pharmaceuticals

Par Pharmaceuticals

Mylan

Sanofi

Novartis

Akorn

Albireo Pharma

Mirum Pharmaceuticals

### Segment by Type

Ursodeoxycholic Acid

Cholestyramine

Rifampicin

Late Stage Pipeline Drugs

Others

## Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

## By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East, Africa, and Latin America

Turkey

Saudi Arabia

UAE

Rest of MEA

## Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment revenue, gross margin, and recent development, etc.

## Chapter 12: Analyst's Viewpoints/Conclusions

## Contents

### 1 REPORT OVERVIEW

#### 1.1 Study Scope

#### 1.2 Market Analysis by Type

1.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029

1.2.2 Ursodeoxycholic Acid

1.2.3 Cholestyramine

1.2.4 Rifampicin

1.2.5 Late Stage Pipeline Drugs

1.2.6 Others

#### 1.3 Market by Application

1.3.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

#### 1.4 Assumptions and Limitations

#### 1.5 Study Objectives

#### 1.6 Years Considered

### 2 GLOBAL GROWTH TRENDS

2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Perspective (2018-2029)

2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Trends by Region

2.2.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Region (2018-2023)

2.2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Region (2024-2029)

2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Dynamics

2.3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Trends

2.3.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers

2.3.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

## Challenges

### 2.3.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

## Restraints

## **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

### 3.1 Global Revenue Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Players

#### 3.1.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2018-2023)

#### 3.1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Players (2018-2023)

### 3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

### 3.3 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023

### 3.4 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Ratio

#### 3.4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Ratio (CR5 and HHI)

#### 3.4.2 Global Top 10 and Top 5 Companies by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2022

### 3.5 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Head office and Area Served

### 3.6 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Product and Application

### 3.7 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Date of Enter into This Industry

### 3.8 Mergers & Acquisitions, Expansion Plans

## **4 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 2 TREATMENT BREAKDOWN DATA BY TYPE**

### 4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Type (2018-2023)

### 4.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2024-2029)

## **5 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 2 TREATMENT**



## **BREAKDOWN DATA BY APPLICATION**

5.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Application (2018-2023)

5.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2024-2029)

## **6 NORTH AMERICA**

6.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)

6.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type

6.2.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023)

6.2.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)

6.2.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

6.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application

6.3.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023)

6.3.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)

6.3.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

6.4 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country

6.4.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country: 2018 VS 2022 VS 2029

6.4.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2023)

6.4.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029)

6.4.4 United States

6.4.5 Canada

## **7 EUROPE**

7.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)

7.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type

7.2.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023)

7.2.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)

7.2.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

7.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application

7.3.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023)

7.3.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)

7.3.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

7.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country

7.4.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country: 2018 VS 2022 VS 2029

7.4.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2023)

7.4.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

## **8 CHINA**

8.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)

8.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size

by Type

8.2.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023)

8.2.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)

8.2.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

8.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application

8.3.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023)

8.3.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)

8.3.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

## **9 ASIA (EXCLUDING CHINA)**

9.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)

9.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type

9.2.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023)

9.2.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)

9.2.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

9.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application

9.3.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023)

9.3.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)

9.3.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

9.4 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region

9.4.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size

by Region: 2018 VS 2022 VS 2029

9.4.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2023)

9.4.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2024-2029)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

## **10 MIDDLE EAST, AFRICA, AND LATIN AMERICA**

10.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)

10.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type

10.2.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023)

10.2.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)

10.2.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

10.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application

10.3.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023)

10.3.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)

10.3.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

10.4 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country

10.4.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country: 2018 VS 2022 VS 2029

10.4.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2023)

10.4.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic

## Cholestasis Type 2 Treatment Market Size by Country (2024-2029)

- 10.4.4 Brazil
- 10.4.5 Mexico
- 10.4.6 Turkey
- 10.4.7 Saudi Arabia
- 10.4.8 Israel
- 10.4.9 GCC Countries

## 11 KEY PLAYERS PROFILES

### 11.1 Teva

- 11.1.1 Teva Company Details
- 11.1.2 Teva Business Overview
- 11.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
- 11.1.4 Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
- 11.1.5 Teva Recent Developments

### 11.2 AbbVie

- 11.2.1 AbbVie Company Details
- 11.2.2 AbbVie Business Overview
- 11.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
- 11.2.4 AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
- 11.2.5 AbbVie Recent Developments

### 11.3 Glenmark Pharmaceuticals

- 11.3.1 Glenmark Pharmaceuticals Company Details
- 11.3.2 Glenmark Pharmaceuticals Business Overview
- 11.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
- 11.3.4 Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
- 11.3.5 Glenmark Pharmaceuticals Recent Developments

### 11.4 Par Pharmaceuticals

- 11.4.1 Par Pharmaceuticals Company Details
- 11.4.2 Par Pharmaceuticals Business Overview
- 11.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction

- 11.4.4 Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
- 11.4.5 Par Pharmaceuticals Recent Developments
- 11.5 Mylan
  - 11.5.1 Mylan Company Details
  - 11.5.2 Mylan Business Overview
  - 11.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
  - 11.5.4 Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
  - 11.5.5 Mylan Recent Developments
- 11.6 Sanofi
  - 11.6.1 Sanofi Company Details
  - 11.6.2 Sanofi Business Overview
  - 11.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
  - 11.6.4 Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
  - 11.6.5 Sanofi Recent Developments
- 11.7 Novartis
  - 11.7.1 Novartis Company Details
  - 11.7.2 Novartis Business Overview
  - 11.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
  - 11.7.4 Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
  - 11.7.5 Novartis Recent Developments
- 11.8 Akorn
  - 11.8.1 Akorn Company Details
  - 11.8.2 Akorn Business Overview
  - 11.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
  - 11.8.4 Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
  - 11.8.5 Akorn Recent Developments
- 11.9 Albireo Pharma
  - 11.9.1 Albireo Pharma Company Details
  - 11.9.2 Albireo Pharma Business Overview
  - 11.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment

## Introduction

11.9.4 Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

11.9.5 Albireo Pharma Recent Developments

## 11.10 Mirum Pharmaceuticals

11.10.1 Mirum Pharmaceuticals Company Details

11.10.2 Mirum Pharmaceuticals Business Overview

11.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2

## Treatment Introduction

11.10.4 Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

11.10.5 Mirum Pharmaceuticals Recent Developments

## **12 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **13 APPENDIX**

### 13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

### 13.2 Disclaimer

### 13.3 Author Details



## List Of Tables

### LIST OF TABLES

Table 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type (US\$ Million), 2018 VS 2022 VS 2029

Table 2. Key Players of Ursodeoxycholic Acid

Table 3. Key Players of Cholestyramine

Table 4. Key Players of Rifampicin

Table 5. Key Players of Late Stage Pipeline Drugs

Table 6. Key Players of Others

Table 7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Application (US\$ Million), 2018 VS 2022 VS 2029

Table 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 9. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2023) & (US\$ Million)

Table 10. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2018-2023)

Table 11. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 12. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2024-2029)

Table 13. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Trends

Table 14. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers

Table 15. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Challenges

Table 16. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Restraints

Table 17. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2018-2023) & (US\$ Million)

Table 18. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Share by Players (2018-2023)

Table 19. Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2022)

Table 20. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment



## Industry Ranking 2021 VS 2022 VS 2023

Table 21. Global 5 Largest Players Market Share by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (CR5 and HHI) & (2018-2023)

Table 22. Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Headquarters and Area Served

Table 23. Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Product and Application

Table 24. Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Product and Application

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 27. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2018-2023)

Table 28. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 29. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2024-2029)

Table 30. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 31. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Share by Application (2018-2023)

Table 32. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 33. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Share by Application (2024-2029)

Table 34. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 35. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US\$ Million)

Table 36. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 37. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US\$ Million)

Table 38. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 39. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 40. North America Progressive Familial Intrahepatic Cholestasis Type 2

Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 41. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 42. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US\$ Million)

Table 43. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 44. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US\$ Million)

Table 45. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 48. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 49. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US\$ Million)

Table 50. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 51. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US\$ Million)

Table 52. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 53. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US\$ Million)

Table 54. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 55. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US\$ Million)

Table 56. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 57. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2023) & (US\$ Million)

Table 58. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2024-2029) & (US\$ Million)

Table 59. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 60. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US\$ Million)

Table 61. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 62. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US\$ Million)

Table 63. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 64. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 65. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 66. Teva Company Details

Table 67. Teva Business Overview

Table 68. Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product

Table 69. Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)

Table 70. Teva Recent Developments

Table 71. AbbVie Company Details

Table 72. AbbVie Business Overview

Table 73. AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product

Table 74. AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)

Table 75. AbbVie Recent Developments

Table 76. Glenmark Pharmaceuticals Company Details

Table 77. Glenmark Pharmaceuticals Business Overview

Table 78. Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product

Table 79. Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)

Table 80. Glenmark Pharmaceuticals Recent Developments

Table 81. Par Pharmaceuticals Company Details

Table 82. Par Pharmaceuticals Business Overview

Table 83. Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product

Table 84. Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)

- Table 85. Par Pharmaceuticals Recent Developments
- Table 86. Mylan Company Details
- Table 87. Mylan Business Overview
- Table 88. Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
- Table 89. Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)
- Table 90. Mylan Recent Developments
- Table 91. Sanofi Company Details
- Table 92. Sanofi Business Overview
- Table 93. Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
- Table 94. Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)
- Table 95. Sanofi Recent Developments
- Table 96. Novartis Company Details
- Table 97. Novartis Business Overview
- Table 98. Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
- Table 99. Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)
- Table 100. Novartis Recent Developments
- Table 101. Akorn Company Details
- Table 102. Akorn Business Overview
- Table 103. Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
- Table 104. Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)
- Table 105. Akorn Recent Developments
- Table 106. Albireo Pharma Company Details
- Table 107. Albireo Pharma Business Overview
- Table 108. Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
- Table 109. Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)
- Table 110. Albireo Pharma Recent Developments
- Table 111. Mirum Pharmaceuticals Company Details
- Table 112. Mirum Pharmaceuticals Business Overview
- Table 113. Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type

## 2 Treatment Product

Table 114. Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023) & (US\$ Million)

Table 115. Mirum Pharmaceuticals Recent Developments

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 2. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type: 2022 VS 2029

Figure 3. Ursodeoxycholic Acid Features

Figure 4. Cholestyramine Features

Figure 5. Rifampicin Features

Figure 6. Late Stage Pipeline Drugs Features

Figure 7. Others Features

Figure 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 9. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application: 2022 VS 2029

Figure 10. Hospital Pharmacies Case Studies

Figure 11. Retail Pharmacies Case Studies

Figure 12. Online Pharmacies Case Studies

Figure 13. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Report Years Considered

Figure 14. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 15. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region: 2022 VS 2029

Figure 17. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Players in 2022

Figure 18. Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2022)

Figure 19. The Top 10 and 5 Players Market Share by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2022

Figure 20. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)



Figure 22. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

Figure 23. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2018-2029)

Figure 24. United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Canada Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US\$ Million)

Figure 27. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

Figure 28. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

Figure 29. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2018-2029)

Figure 30. Germany Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. France Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. U.K. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Italy Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Russia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Nordic Countries Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US\$ Million)

Figure 37. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

Figure 38. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

Figure 39. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US\$ Million)

Figure 40. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

Figure 41. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

Share by Application (2018-2029)

Figure 42. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2018-2029)

Figure 43. Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. South Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. China Taiwan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Australia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 49. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US\$ Million)

Figure 50. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)

Figure 51. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)

Figure 52. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2018-2029)

Figure 53. Brazil Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 54. Mexico Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 55. Turkey Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 56. Saudi Arabia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 57. Israel Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 58. GCC Countries Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 59. Teva Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 60. AbbVie Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)



Figure 61. Glenmark Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 62. Par Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 63. Mylan Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 64. Sanofi Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 65. Novartis Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 66. Akorn Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 67. Albireo Pharma Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 68. Mirum Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

## I would like to order

Product name: Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Insights, Forecast to 2029

Product link: <https://marketpublishers.com/r/G7F7EB2CFB71EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7F7EB2CFB71EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

